PMID- 35066728
OWN - NLM
STAT- MEDLINE
DCOM- 20230529
LR  - 20230529
IS  - 1591-9528 (Electronic)
IS  - 1591-8890 (Linking)
VI  - 23
IP  - 2
DP  - 2023 Jun
TI  - Venetoclax combined with hypomethylating agents or low-dose cytarabine as 
      induction chemotherapy for patients with untreated acute myeloid leukemia 
      ineligible for intensive chemotherapy: a systematic review and meta-analysis.
PG  - 219-227
LID - 10.1007/s10238-021-00784-y [doi]
AB  - The treatment of patients with acute myeloid leukemia (AML) who are intolerable 
      to intensive chemotherapy remains to be further explored. Recent studies have 
      shown that venetoclax combined with hypomethylating agents (HMAs) or low-dose 
      cytarabine (LDAC) may have a good effect on these patients. Given the lack of a 
      comprehensive analysis of the efficacy and safety of such treatment, the aim of 
      this review was to assess the efficacy and safety of venetoclax plus HMAs or LDAC 
      for untreated AML patients who are ineligible for intensive chemotherapy. A 
      systematic literature review was conducted in the PubMed, Embase, and Cochrane 
      databases up to April 30, 2021. A total of four clinical trials including 440 
      patients were eligible for this meta-analysis. The pooled complete remission (CR) 
      and complete remission plus complete remission with incomplete blood count 
      recovery (CR/CRi) rates were 0.40 (95% CI 0.26-0.55) and 0.64 (95% CI 0.49-0.77), 
      respectively. The median overall survival time was 11.7 (95% CI 10.15-14.18) 
      months. The most common adverse events (AEs) of any grade were nausea (57%), 
      diarrhea (42%), and hypokalemia (36%). The most common AEs of grade >/= 3 were 
      febrile neutropenia (38%) and thrombocytopenia (35%). The pooled 30-day mortality 
      rate in our study was 5%. The improved remission rate and tolerance make 
      venetoclax combined with HMAs or LDAC an attractive induction therapy option for 
      untreated AML patients who are unsuitable for intensive chemotherapy.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Qin, Yao
AU  - Qin Y
AD  - Department of Hematology, West China Hospital, Sichuan University, No. 37, Guoxue 
      Xiang, Chengdu, 610041, Sichuan, China.
FAU - Kuang, Pu
AU  - Kuang P
AUID- ORCID: 0000-0002-1007-6784
AD  - Department of Hematology, West China Hospital, Sichuan University, No. 37, Guoxue 
      Xiang, Chengdu, 610041, Sichuan, China. pukuang@foxmail.com.
FAU - Liu, Ting
AU  - Liu T
AD  - Department of Hematology, West China Hospital, Sichuan University, No. 37, Guoxue 
      Xiang, Chengdu, 610041, Sichuan, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220123
PL  - Italy
TA  - Clin Exp Med
JT  - Clinical and experimental medicine
JID - 100973405
RN  - 04079A1RDZ (Cytarabine)
RN  - N54AIC43PW (venetoclax)
RN  - 0 (Bridged Bicyclo Compounds, Heterocyclic)
SB  - IM
MH  - Humans
MH  - *Cytarabine/adverse effects
MH  - Induction Chemotherapy
MH  - *Leukemia, Myeloid, Acute/drug therapy/etiology
MH  - Bridged Bicyclo Compounds, Heterocyclic/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Hypomethylating agents
OT  - Low-dose cytarabine
OT  - Meta-analysis
OT  - Systematic review
OT  - Venetoclax
EDAT- 2022/01/24 06:00
MHDA- 2023/05/29 06:42
CRDT- 2022/01/23 20:38
PHST- 2021/05/15 00:00 [received]
PHST- 2021/12/10 00:00 [accepted]
PHST- 2023/05/29 06:42 [medline]
PHST- 2022/01/24 06:00 [pubmed]
PHST- 2022/01/23 20:38 [entrez]
AID - 10.1007/s10238-021-00784-y [pii]
AID - 10.1007/s10238-021-00784-y [doi]
PST - ppublish
SO  - Clin Exp Med. 2023 Jun;23(2):219-227. doi: 10.1007/s10238-021-00784-y. Epub 2022 
      Jan 23.